Macquarie Group
SCLN

Macquarie Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Macquarie Group’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,500
Closed -$44K – 1584
2017
Q1 		$44K Sell
4,500
-8,300
-65% -$82.9K ﹤0.01% 1508
2016
Q4 		$138K Sell
12,800
-6,800
-35% -$68K ﹤0.01% 1469
2016
Q3 		$201K Sell
19,600
-91,200
-82% -$993K ﹤0.01% 1408
2016
Q2 		$1.45M Buy
110,800
+29,500
+36% +$387K ﹤0.01% 1214
2016
Q1 		$894K Buy
+81,300
New +$723K ﹤0.01% 1147

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macquarie Group's SCLN Position: Q2 2017 in Review

Macquarie Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2017, closing a stake of 4,500 shares — an estimated $44K sold.

Macquarie Group first reported a position in SCLN in Q1 2016 and held it in 5 quarters. The position peaked at $1.45M in Q2 2016. 142 funds tracked by Wall St. Rank hold SCLN as of Q2 2017.

  • Macquarie Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Macquarie Group sold 4,500 Sciclone Pharmaceuticals Inc shares in Q2 2017, an estimated $44K.
  • Macquarie Group first reported a position in Sciclone Pharmaceuticals Inc in Q1 2016 and held it in 5 quarters.
  • Macquarie Group's Sciclone Pharmaceuticals Inc position peaked at $1.45M in Q2 2016.
  • 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2017.

Based on Macquarie Group's 13F filing for Q2 2017, filed 14 Aug 2017.